THE WOODLANDS, Texas--(BUSINESS WIRE)--On August 7, 2009, Repros Therapeutics Inc. (NasdaqGM:RPRX) received notification of a class action complaint against it and certain of its officers and directors, on behalf of shareholders who purchased Repros common stock between July 1, 2009 and August 3, 2009. The complaint alleges that defendants violated certain provisions of the Securities Exchange Act of 1934 by issuing materially false and misleading press releases regarding the results of clinical trials for its drug Proellex. Repros is currently assessing all possible courses of action with respect to such complaint.
